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LETTERS TO THE EDITOR
Ventricular Reduction Therapy:
Controlled Clinical Trials Overdue
Laks and Marelli’s article on left ventricular reduction therapy (1)
is an excellent presentation of the state of the art. Although this is
not to criticize the authors, their discussion raises an issue that
should have been considered from the inception of this therapy and
is embodied in the penultimate sentence of the report: “Ultimately,
a randomized trial will be required to evaluate this procedure.” The
case for randomized trials of all new therapies (2,3), including
randomization from Patient no. 1 (4), has already been made on
scientific, ethical and indeed behavioral (5) grounds. I will not
belabor it. Unfortunately, this new radical though promising form
of therapy has the disadvantage of a relapse to the “bad old days”
when surgical therapies were considered immune to scientific trials
(6). Originators of new therapies must realize that from Patient no.
1, they really do not know the results. Therefore, on ethical as well
as scientific grounds, patients should be randomized immediately
to give them a “50/50 chance” not to get the new therapy, which
could always be no better or even worse than existing therapy (4).
Therapeutic innovators cannot know the outcome when they begin
to apply any objectively untested treatment. This also applies to the
“learning curve” in which interventionalists, including surgeons,
become technically better with experience (4). Moreover, in any
randomized trial, truly informed consent (versus advised consent)
would let patients know that the trialists have reasonable hopes,
but cannot promise results. (If they did know, a controlled trial
would become unethical because it would deny half of the patients
treatments the trialists consider to be successful). In randomizing
the first patient, hopeful investigators would have half of the
number of patients at any time, but if they are ethical (i.e., honest)
they may be sparing the other half harmful procedures, particularly
when it cannot be known for whom even an ultimately successful
procedure might be contraindicated and could only be developed
with appropriate denominators (2) (i.e., appropriate comparison
groups). As with so many procedures in the past, “ultimately,” as
stated by the authors (1), a trial may be forced, but with what
explanations will patients be recruited?
Finally, this is the day of “evidence-based-medicine”—mainly
on a basis of randomized, controlled clinical trials. This was
rejected ab initio by the originators of ventricular reduction. After
all, “Science teaches us to doubt, and, in ignorance, to refrain.” In
this admonition from Claude Bernard, the word “ethics” can be
substituted for “science” (7). As always, the scientific case and the
ethical case are the same (3).
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REPLY
We appreciate Dr. Spodick’s letter, which suggests an immediate
need to initiate a controlled trial of partial left ventriculectomy
(PLV). Although we do not wish to agree or disagree on the
timing of such a trial, we would like to address several specific
questions that designing such a study raises.
To justify a controlled clinical trial, one must first establish that
there is uncertainty among experts as to treatment preference for a
given group of patients. This is defined as “equipoise” (1). Effective
equipoise has been described as the exact point when the most
likely results of a proposed trial are thought to be an improvement
sufficient to compensate for the disadvantage of the treatment with
the greatest risk (2). Equipoise implies that we, as a group, have no
rational preference for treatment arm A or B. This collective group
has been further defined to include both physicians and the
patients who are to be enrolled in such a study (3,4). This
condition is essential to ensure an adequate informed consent
protocol that protect patients from harmful therapies (5,6). To
perfectly respect patient autonomy, it has been suggested that
patients should be free to choose either arm of a trial, or the
randomization alternative.
For the purpose of discussion, one can assume that PLV
currently achieves 70% success rates at short-term follow-up in
selected patients. With this as a valuable result, PLV could be
among the available treatments for end-stage congestive heart
failure, although not definitively. This implies a surgical procedure
with its inherent risks, which may then require another operation
(transplantation) later on for many patients. Indeed, this has been
observed in the existing reported results.
Past experience with mechanical assist devices has taught us that
a benefit may occur after surgical technique and technology evolve.
In the early experience, some thought that it was not justified to
bridge critically ill patients with an expensive treatment that would
prolong waiting time for a scarce resource (7). We now know that
implantable left ventricular assist devices (LVADs) can maintain
patients’ physical condition (currently as outpatients in many cases)
so that the few donor hearts that are available are not risked for
patients too sick to tolerate transplant surgery (8). Implantable
LVADs are now being studied as a destination therapy. The
cardiomyoplasty trial, in contrast, demonstrated the difficulties in
systematically offering an operation to patients who were relatively
well treated with maximal outpatient medical treatment (unpub-
lished data). The difference with implantable LVADs is that these
were offered to critically ill status I patients receiving maximal
intravenous therapy who were starting to show signs of end-organ
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dysfunction. Because such a cohort faced a very poor outcome,
offering a procedure that potentially had a 20% mortality rate was
(and still is) rational. Transplantation has a 5% mortality rate in
optimized patients and a 70% five-year survival rate (9). Timing of
surgical treatment is therefore based on specific knowledge of
natural history reflected by the presence of factors that precisely
define the prognosis.
Available current data do not point to equipoise between PLV
and heart transplantation, particularly because long-term results
are unknown. In addition, with ongoing refinements, medical
treatment of congestive heart failure complemented by implantable
LVADs has contributed to a plateau in the number of deaths of
patients waiting for a heart transplant in the U.S. (http.//
www.unos.org). This has been true for the past several years,
despite the increasing gap between the number of patients being
listed for heart transplants and the number of heart transplants
being performed.
This line of reasoning would indicate that with our present
knowledge, which is limited by long-term follow-up, a controlled
trial of PLV should be aimed at patients with congestive heart
failure who are at greatest risk of dying while waiting for an
available donor heart. Such patients stand to benefit the most from
such a therapy. The alternative arm of such a trial would be
maximal medical therapy, including inotropic agents, and implant-
able LVADs. One could then imagine a scenario in which the
possibility of entering such a trial would be presented to class IV
patients who are or about to reach status I and are also ideal
selected candidates for PLV (e.g., dilated cardiomyopathy with left
ventricular end-diastolic dimension .70 mm and preserved LV
wall thickness). Because patients in both arms of the trial would
remain listed for transplantation, follow-up would theoretically be
equal for both the LVAD and PLV group. Such a trial would also
provide the possibility for patients to cross over from the PLV
group to the LVAD group. At the other end of the spectrum,
another outcome of such a trial strategy would be for patients and
treating physicians in the PLV group to choose to prolong the
bridge period and avoid transplant surgery.
As long-term data regarding PLV become available, a more
precise trial could separate class III and IV patients into two
separate trials with different end points. Indeed, current knowledge
may not be developed enough to design the most meaningful
randomized trial possible.
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Is Electron Beam Computed Tomography the
Sole Detection Method for Coronary Calcium?
Budoff et al. (1) emphasized the advantages of electron beam
computed tomography (CT) over the currently used noninvasive
imaging exercise techniques to distinguish between ischemic and
nonischemic cardiomyopathy. However, other techniques that
noninvasively detect coronary calcification, fluoroscopy and spiral
CT have been used for the same purpose but were inexplicably
omitted from their discussion. This omission mistakenly creates
the impression to readers that electron beam CT is the sole
available technique. Twenty years ago, Johnson et al. (2) used
fluoroscopy for the diagnosis of the ischemic type of cardiomyop-
athy, a report that Hurst’s textbook of cardiology did not neglect to
mention (3). Spiral CT is another widely available alternative for
the detection of coronary calcium, which we have reported (4–8)
and which has been published by others (9). The new generation
of spiral techniques are based on the ability to scan the heart within
a single breathold, despite the lack of electrocardiographic trigger-
ing. The value of dual-slice spiral CT for the differentiation of
ischemic from nonischemic dilated cardiomyopathy was reported 3
years ago (4). Budoff et al. confirmed the results of this study and
reproduced them: The diagnosis of ischemic cardiomyopathy
based on the presence of calcium by spiral CT (total score .0)
yielded sensitivity, specificity and total accuracy rates of 100%, 92%
and 97%, respectively, compared with 99%, 83% and 92%, respec-
tively, in their study. The relatively reduced specificity found by
Budoff et al. is probably attributable to their definition of dilated
cardiomyopathy, which was based solely on a left ventricular
ejection fraction ,40%, regardless of the left ventricular end-
diastolic volume. The main clinical relevance of both studies is the
contribution of fast CT techniques to the noninvasive diagnosis of
cardiomyopathy of unknown etiology. In these patients, the
absence of coronary calcium indicates a nonischemic etiology and
can rule out the necessity for coronary angiography.
One would expect the original reports to be highlighted by
Budoff et al. to strengthen their findings. Instead, they mysteri-
ously chose to ignore them. Was this a mere oversight?
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